Natera, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Steven Leonard Chapman
- Full Time Employees
- 6,138
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 13011 McCallen Pass Building A Austin TX United States of America 78753
- IPO Date
- Jul 1, 2015
- CIK
- 0001604821
- Website
- natera.com
- Similar Companies
- Business
- Natera, Inc. (NTRA) is a global leader in cell-free DNA (cfDNA) testing, specializing in noninvasive molecular diagnostics for oncology, women's health, and organ health. Founded in 2004 and headquartered in Austin, Texas, the company operates CAP-accredited and CLIA-certified laboratories in Austin, Texas, and San Carlos, California, with a global presence including facilities in the Netherlands and partnerships extending services to numerous countries worldwide. Natera leverages proprietary technology combining novel molecular biology and bioinformatics to detect genetic material from blood samples, enabling early risk assessment, recurrence detection, and personalized treatment decisions for clinicians and patients. The company's core offerings span women's health tests including Panorama, a non-invasive prenatal test (NIPT) screening for fetal chromosomal abnormalities such as Down syndrome with positive predictive value reporting; Horizon, advanced carrier screening for hundreds of genetic conditions; Vistara, single-gene NIPT for 25 additional conditions; Anora, a miscarriage analysis test; Spectrum, preimplantation genetic testing for IVF embryos; and Empower for hereditary cancer risk. In oncology, Natera provides Signatera, a personalized circulating tumor DNA (ctDNA) test for molecular residual disease (MRD) monitoring, recurrence detection, and treatment response evaluation across cancers like colorectal, bladder, lymphoma, and multiple myeloma; Altera for tumor genomic profiling to identify somatic mutations and clinical trials; Latitude, a tissue-free MRD test; and Empower for germline mutations. Organ health solutions feature Prospera, a donor-derived cfDNA test for kidney transplant rejection assessment. Recent developments include the launch of Signatera Genome, a genome-designed MRD assay achieving Medicare coverage; Latitude Tissue-Free MRD; Fetal Focus single-gene NIPT with an expanded version forthcoming; and a Panorama vanishing twin workflow. Natera raised its 2025 revenue guidance to $2.18-$2.26 billion following strong Q3 2025 results with record revenues and oncology test volume growth of 46.1% year-over-year, alongside plans for seven new MolDX submissions potentially worth $250-$300 million in gross profit. Strategic partnerships with BGI Genomics Co., Ltd. and Foundation Medicine, Inc. enhance genetic testing capabilities and market expansion in precision medicine, while new data from trials like IMvigor011 and upcoming presentations at the 2025 American Society of Hematology meeting underscore ongoing clinical validation.
Company News
Natera Gains 118.1% in a Year: What's Driving the Rally?
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
Which Healthcare ETF Is the Better Buy: Fidelity’s Broad FHLC or Invesco’s Biotech-Focused PBE?
FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay
HWG Holdings LP Makes New $9.82 Million Investment in Natera, Inc. $NTRA
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
Natera (NASDAQ:NTRA) Hits New 12-Month High – Here’s Why
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Natera (NASDAQ:NTRA) CEO Sells 1,273 Shares of Company Stock
Natera (NASDAQ: NTRA) insider sells 3,000 shares in a planned trade
The Top HealthTech Questions Landing on Our Desks
Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades'
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
Natera (NASDAQ:NTRA) Hits New 12-Month High – Here’s Why
3 Analysts, 3 Trades to Make Today
Uber, Micron, Datadog And A Health Care Stock: CNBC's ‘Final Trades'
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer